Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those per...

Descripción completa

Detalles Bibliográficos
Autores: Espinosa-Pereiro, Juan|||0000-0002-7238-8337, Ghimire, Samiksha|||0000-0002-6028-1460, Sturkenboom, Marieke G. G.|||0000-0002-3420-0591, Alffenaar, Jan-Willem C.|||0000-0001-6703-0288, Tavares, Margarida|||0000-0003-4518-2197, Aguirre, Sarita|||0000-0002-8752-2762, Battaglia, Arturo, Molinas, Gladys, Tórtola Fernández, María Teresa|||0000-0002-9188-298X, Akkerman, Onno|||0000-0001-5638-9260, Sánchez Montalvá, Adrián|||0000-0002-2194-5447, Magis-Escurra, Cecile|||0000-0001-8424-9425
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:305748
Acceso en línea:https://ddd.uab.cat/record/305748
https://dx.doi.org/urn:doi:10.3390/pharmaceutics15010009
Access Level:acceso abierto
Palabra clave:Tuberculosis
Rifampicin
Clinical trial
Vulnerable population
Descripción
Sumario:Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those persons with TB and a good baseline prognosis, or increased treatment success for vulnerable subgroups (age.

Similares en LA Referencia